Keith Cengel, MD, PhD

Radiation Oncology
Accepting new patients
Sees patients age 18 and up
Penn Radiation Oncology Perelman - 2nd Floor
View 2 additional locations
Penn Medicine Provider

About me

  • Executive Director, Penn Mesothelioma and Pleural Diseases Program
  • Director, Photodynamic Therapy Program
  • Professor of Radiation Oncology at the Hospital of the University of Pennsylvania

My education and training

  • Medical School: University of Illinois College of Medicine Rockford
  • Residency: University of Illinois at Chicago
  • Residency: University of Pennsylvania Health System

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Chester County Hospital: Has privileges to treat patients in the hospital.
Dr. Cengel is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Hongjing Sun 1 2, Michele M Kim 1, Andreea Dimofte 1, Sunil Singhal 3, Keith A Cengel 1, Timothy C Zhu 1 3D Reactive Oxygen Species Dosimetry in Pleural Photodynamic Therapy: Integration of Macroscopic Kinetic Modeling and Deformable Registration , Antioxidants (Basel) . : 2026


Cole Friedes 1, Michelle Iocolano 1, Nikhil Yegya-Raman 1, John C Kucharczuk 2, Taine T V Pechet 2, Roger B Cohen 3, Charu Aggarwal 3, Melina E Marmarelis 3, William P Levin 1, Keith A Cengel 1, Christine A Ciunci 3, Christopher D'Avella 3, Aditi P Singh 3, Christiana W Davis 3, Corey J Langer 3, Jeffrey Bradley 1, Steven J Feigenberg 3 Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy , Am J Clin Oncol .: 2026


Wei Zou 1, Lei Dong 2, Arnaud Pin 3, Rasmus Nilsson 4, Michele Kim 2, Ontida Apinorasethkul 2, Julia Pakela 2, Andrew Friberg 2, Brandon Koger 2, Rudi Labarbe 3, Carolina Llina Fuentes 3, Keith Cengel 2, Erik Traneus 4, Swati Girdhani 3, Costas Koumenis 2, Francois Vander Stappen 3, Eric Diffenderfer 2, Jeffrey Bradley 2, Boon-Keng Kevin Teo 2, Alexander Lin 2 Deliverable proton conformal FLASH radiotherapy treatment planning for head and neck re-irradiation patients , Radiother Oncol . : 2026


Cole Friedes 1, Nikhil Yegya-Raman 2, Michelle Iocolano 2, William P Levin 2, Keith A Cengel 2, Jeffrey D Bradley 2, Steven J Feigenberg 2 Primary Tumor Failure After Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Brief Report on the Implications for NRG LU-008 , Int J Radiat Oncol Biol Phys .: 2026


Cole Friedes 1, Nikhil Yegya-Raman 2, Michelle Iocolano 2, William P Levin 2, Keith A Cengel 2, Jeffrey D Bradley 2, Steven J Feigenberg 2 Primary Tumor Failure After Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Brief Report on the Implications for NRG LU-008 , Int J Radiat Oncol Biol Phys .: 2026


Zou W, Dong L, Pin A, Nilsson R, Kim M, Apinorasethkul O, Pakela J, Friberg A, Koger B, Labarbe R, Fuentes CL, Cengel K, Traneus E, Girdhani S, Koumenis C, Vander Stappen F, Diffenderfer E, Bradley J, Teo BK, Lin A. Deliverable proton conformal FLASH radiotherapy treatment planning for head and neck re-irradiation patients , Radiother Oncol, 216: 2025,111349


Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ. Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy , Am J Clin Oncol: 2025


Friedes C, Yegya-Raman N, Iocolano M, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ. Primary Tumor Failure After Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Brief Report on the Implications for NRG LU-008 , Int J Radiat Oncol Biol Phys: 2025


Friberg AM, Tan HS, Diffenderfer ES, Verginadis I, Kim MM, Cengel K, Wiersma R, Dong L, Koumenis C, Teo BK, Zou W. Physicochemical indication of the FLASH effect from shoot-through proton pencil beam scanning parameters delivered under ultra-high dose rates , Phys Med Biol, 70: 2025,175002


Feigenberg SJ, Costabile F, Tanes C, Bittinger K, O'Connor R, Agarwal D, Skoufos G, Salaris S, Hatzigeorgiou A, Kostopoulos N, Lloyd S, Friedes C, Chen L, Yegya-Raman N, Cengel K, Levin W, Valentić B, Quarton T, Shestov AA, Berman A, Bradley J, Maity A, Koumenis C, Ben-Josef E, Facciabene A. Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study , J Immunother Cancer, 13: 2025,e011356


View all publications